ILA 505.9
(-1.23%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | 21.2 Million | 7.08 Million | 45.62 Million | -9.57 Million | -13.61 Million | -9.85 Million |
Net Income | 96.41 Million | 163.7 Million | 172.12 Million | 132.68 Million | 17.37 Million | 35.36 Million |
Depreciation & Amortization | 25.34 Million | 11.02 Million | 6.57 Million | 4.23 Million | 6000.00 | 30 Thousand |
Deferred income taxes | - | - | -126.51 Million | -58.46 Million | -6000.00 | - |
Stock-based compensation | 651 Thousand | 1.7 Million | 2.35 Million | 1.03 Million | 128 Thousand | 306 Thousand |
Change in working capital | -12.82 Million | -30.59 Million | -2.95 Million | 1.26 Million | -2.15 Million | -2.76 Million |
Other non-cash items | -88.38 Million | -138.75 Million | -5.96 Million | -90.32 Million | -28.96 Million | -42.75 Million |
Investing Cash Flow | -143.7 Million | -143.92 Million | -132.26 Million | -340.49 Million | -14.22 Million | -52.34 Million |
Investments in PPE | -30.59 Million | -42.57 Million | -7.46 Million | -2.1 Million | -48 Thousand | -788 Thousand |
Acquisitions | -47.28 Million | -123.01 Million | -72.11 Million | -327.67 Million | -13.06 Million | -3.92 Million |
Investment purchases | - | - | -19.99 Million | -9.97 Million | -12.5 Million | - |
Sales/Maturities of investments | - | - | 20.9 Million | 10.29 Million | 1.49 Million | - |
Other Investing Activities | -65.82 Million | 21.66 Million | -53.59 Million | -11.03 Million | 9.89 Million | -47.63 Million |
Financing Cash Flow | 224.44 Million | 161.42 Million | 121.98 Million | 353.72 Million | 3.23 Million | 52.83 Million |
Debt repayment | -243.44 Million | -159.49 Million | -59.76 Million | -114.89 Million | -6.1 Million | -21.82 Million |
Dividends payments | -39.99 Million | - | -20 Million | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | 15 Million | 74.53 Million | 254.76 Million | 4.38 Million | 4.04 Million |
Other Financing Activities | 20.99 Million | 305.92 Million | 82.22 Million | 213.85 Million | 4.95 Million | 70.61 Million |
Accounts receivables | -12.82 Million | -12.53 Million | -1.68 Million | 684 Thousand | -792 Thousand | -14 Thousand |
Accounts payables | - | - | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | - | -18.06 Million | -1.27 Million | 578 Thousand | -1.36 Million | - |
Cash at beginning of period | 77.79 Million | 53.38 Million | 18.97 Million | 22.24 Million | 9.51 Million | 18.75 Million |
Cash at end of period | 180.84 Million | 77.79 Million | 53.38 Million | 18.97 Million | 22.24 Million | 9.51 Million |
Capital Expenditure | -30.59 Million | -42.57 Million | -7.46 Million | -2.1 Million | -48 Thousand | -788 Thousand |
Effect of forex changes on cash | 1.1 Million | -172 Thousand | -943 Thousand | -6.92 Million | -793 Thousand | 130 Thousand |
Net cash flow / Change in cash | 103.05 Million | 24.4 Million | 34.4 Million | -3.26 Million | 12.72 Million | -9.23 Million |
Free Cash Flow | -9.39 Million | -35.49 Million | 38.15 Million | -11.67 Million | -13.66 Million | -10.63 Million |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 63.36 Million | 5.9 Million | 96.41 Million | 22.69 Million | 17.85 Million | 59.97 Million |
Depreciation & Amortization | 6.93 Million | 6.45 Million | 25.34 Million | 7.5 Million | 7.91 Million | 5.2 Million |
Deferred income taxes | - | - | - | - | -10.92 Million | -61.64 Million |
Stock-based compensation | 93 Thousand | 93 Thousand | 651 Thousand | 108.5 Thousand | 124 Thousand | 217 Thousand |
Change in working capital | 5.35 Million | -11.52 Million | -12.82 Million | 4.63 Million | 5.45 Million | -10.91 Million |
Other non-cash items | 7.16 Million | -10.32 Million | -88.38 Million | -15.47 Million | 2.08 Million | 787 Thousand |
Investing Cash Flow | -31.83 Million | -11.71 Million | -143.7 Million | -14.19 Million | -48.86 Million | -16.78 Million |
Investments in PPE | -12.58 Million | -7.26 Million | -30.59 Million | -6.62 Million | -11.46 Million | -5.6 Million |
Acquisitions | -12.1 Million | 809 Thousand | -47.28 Million | -1.63 Million | -2.72 Million | 4.82 Million |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | -1.92 Million | -4.44 Million | -65.82 Million | -5.93 Million | -34.67 Million | -16 Million |
Financing Cash Flow | 20.83 Million | 67.3 Million | 224.44 Million | -21.09 Million | -12.96 Million | -874 Thousand |
Debt repayment | -60.96 Million | -109.31 Million | -243.44 Million | - | -18.59 Million | -24.4 Million |
Dividends payments | -37.99 Million | - | -39.99 Million | - | - | -39.99 Million |
Common Stock Repurchased | - | -40 Million | - | - | - | 28.98 Million |
Common Stock Issuance | - | - | - | - | - | 38.51 Million |
Other Financing Activities | -2.13 Million | -23.52 Million | 20.99 Million | -21.09 Million | 5.63 Million | -3.97 Million |
Accounts receivables | -5.75 Million | -7.78 Million | -12.82 Million | 4.63 Million | 4.63 Million | -13.39 Million |
Accounts payables | - | - | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | 11.11 Million | - | - | - | 820 Thousand | 2.48 Million |
Cash at beginning of period | 218.39 Million | 180.84 Million | 77.79 Million | - | 212.46 Million | 236.16 Million |
Cash at end of period | 218.84 Million | 218.39 Million | 180.84 Million | -15.8 Million | 173.25 Million | 212.46 Million |
Capital Expenditure | -12.58 Million | -7.26 Million | -30.59 Million | -6.62 Million | -11.46 Million | -5.6 Million |
Effect of forex changes on cash | 45 Thousand | -79 Thousand | 1.1 Million | 4000.00 | 104 Thousand | 322 Thousand |
Net cash flow / Change in cash | 452 Thousand | 37.54 Million | 103.05 Million | -15.8 Million | -39.2 Million | -23.7 Million |
Free Cash Flow | -1.17 Million | -25.23 Million | -9.39 Million | 12.85 Million | 11.05 Million | -11.97 Million |
600552
POST
LR
IRLAB-A
CDNAF
9852